此外，Karyopharm已实施1比15的反向拆股，以符合纳斯达克最低投标价格要求。这一战略举措已获得股东批准，旨在保持公司在纳斯达克全球精选市场的上市地位。在分析师方面，Piper Sandler已将Karyopharm股票的目标价从75美元大幅下调至15美元，同时维持"增持"评级。与此同时，H.C. Wainwright重申了"买入"评级，目标价为7.00美元，并注意到公司的财务业绩和未来预测 ...

$KPTI insiders have traded $KPTI stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.

We recently compiled a list of the 10 Best One-Dollar Stocks To Buy Now. In this article, we are going to take a look at where Karyopharm Therapeutics Inc. (NASDAQ:KPTI) stands against the other ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Michael Mano, the SVP of $KPTI, sold 2,793 shares of the company on 03-04-2025 for an estimated $17,567. We received data on the trade from a recent SEC filing. This ...

Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.36 per share a year ago.

H.C. Wainwright analyst Edward White maintained a Buy rating on Karyopharm Therapeutics (NASDAQ:KPTI) on Monday, setting a price... H.C. Wainwright analyst Edward White maintained a Buy rating on ...

Piper Sandler analyst Edward Tenthoff maintained a Buy rating on Karyopharm Therapeutics (KPTI – Research Report) today and set a price target of $15.00. The company’s shares closed yesterday ...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) stock has reached a 52-week low, trading at $7.58, as the biopharmaceutical company ...

Explore Karyopharm Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for KPTI. Down -12.14% in 4 Weeks, Here's Why Karyopharm Therapeutics Looks ...